CRISPR Therapeutics And Vertex Pharmaceuticals Incorporated Announce That The First Patient Has Been Enrolled In A Phase 1/2 Clinical Study Of Ctx001 In Severe Scd In The U.S. And Is Expected To Be Infused With Ctx001 In Mid-2019